Optimising Outcomes in Chronic Myeloid Leukaemia Through Rational Drug Selection Using Predictive Assay Results and Maximising Treatment Free Remissions

尽管慢性髓系白血病的治疗结果总体上是很好的，但仍然存在一些重要的问题。在这笔赠款中，我们建议：i)使用可预测治疗反应的生物标记物，对新诊断的患者进行个性化的一线治疗选择；ii)提高打算停止治疗的患者的治愈概率；iii)使用超灵敏的分子测试进行疾病检测，以预测疾病复发的风险。

Although outcomes in chronic myeloid leukaemia are generally excellent, a number of important questions remain. In this grant, we propose to i) personalise the selection of frontline treatment for newly diagnosed patients, using biomarkers which can predict treatment response; ii) improve the probability of cure in patients aiming to stop their treatment, and iii) use ultra-sensitive molecular tests for disease detection to predict risk of disease relapse.